NewsHK
Medical device procurement in the safety-needle segment shifted in the second quarter, driven by a return to seasonal buying norms after an atypical flu-season rush in 2025.
Retractable Technologies (NYSE American: RVP) reported $7.2 million in net sales for the three months ended June 30, 2026, down from $10.4 million in the same period a year earlier, with an operating loss of $5.1 million that matched the prior-year figure exactly.
What moved the numbers The year-over-year revenue decline was shaped less by structural demand loss and more by timing.
Management said purchasing patterns in the second quarter of 2025 were unusually concentrated, pulling flu-season EasyPoint needle orders forward into that period.
Keep reading